Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients

Area of Science:

• Hepatology
• Oncology
• Hematology

Background:

• Chronic hepatitis C is associated with elevated serum alpha-fetoprotein (AFP), a marker for hepatocellular carcinoma.
• Iron overload can exacerbate liver damage and fibrosis in chronic hepatitis C.
• Therapeutic phlebotomy is used to reduce iron levels in various conditions.

Purpose of the Study:

• To investigate the impact of iron reduction via therapeutic phlebotomy on serum AFP levels in chronic hepatitis C patients.
• To assess changes in liver enzymes and ferritin levels following phlebotomy.
• To identify factors associated with AFP normalization after iron reduction therapy.

Main Methods:

• Retrospective analysis of 26 chronic hepatitis C patients undergoing repeated therapeutic phlebotomies for iron depletion.
• Measurement of serum AFP, ALT, GGT, and ferritin levels before and after phlebotomy.
• Correlation and multivariate analyses to determine relationships between biochemical markers and AFP normalization.

Main Results:

• Therapeutic phlebotomy significantly reduced median serum AFP (13 to 7 ng/mL), ALT (96 to 50 IU/L), GGT (55 to 28 IU/L), and ferritin (191 to 10 ng/mL) (P < 0.001).
• AFP decline correlated positively with GGT decline (r = 0.695, P = 0.001).
• Post-treatment AFP normalization (<10 ng/mL) occurred in 50% of patients with elevated baseline AFP. Lower post-treatment GGT (<30 IU/L) was an independent predictor of AFP normalization (OR, 21; P = 0.024).

Conclusions:

• Iron reduction through therapeutic phlebotomy is effective in lowering serum AFP and GGT levels in chronic hepatitis C patients.
• Phlebotomy-induced iron depletion may contribute to reduced hepatocellular carcinoma risk markers.
• Monitoring GGT levels post-treatment can help predict AFP normalization in these patients.